Drug Trial Radar · NCT05595642
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,380
Actual
Start
Dec 29, 2022
Primary completion
Jun 24, 2025
Study completion Aug 19, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AstegolimabDrug
Participants will receive SC astegolimab Q2W or Q4W
PlaceboDrug
Participants will receive SC placebo Q2W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment PeriodTime frame: Up to 52 weeks
Locations
348 sites in 36 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS
Dothan, Alabama
Pulmonary Associates PA
Glendale, Arizona
AES - DRS - Synexus Clinical Research US, Inc. - Tucson
Tucson, Arizona
Kern Research
Bakersfield, California
Allergy & Asthma Medical Group of the Bay Area
Walnut Creek, California
Finlay Medical Research Corporation
Greenacres City, Florida
San Marcus Research Clinic Inc.
Miami, Florida
Oceane7 Medical & Research Center, Inc.
Miami, Florida
Avantis Clinical Research, LLC
Miami, Florida
Research Institute of South Florida Inc
Miami, Florida
Diverse Clinical Research, LLC
Miami, Florida
Central Florida Pulmonary Group, PA
Orlando, Florida
AES - DRS - Synexus Clinical Research US, Inc. - The Villages
The Villages, Florida
AES - DRS - Synexus Clinical Research US, Inc. - Atlanta
Atlanta, Georgia
Allergy Center at Brookstone Research - Centricity Research - HyperCore - PPD
Columbus, Georgia
Pivotal Research Solutions
Stonecrest, Georgia
ASHA Clinical Research - ClinEdge - PPDS
Hammond, Indiana
The Research Group of Lexington, LLC
Lexington, Kentucky
Best Clinical Trials
New Orleans, Louisiana
Paul A. Shapero, MD, PA
Bangor, Maine
Pulmonary Research Institute of Southeast Michigan
Farmington Hills, Michigan
Flushing Road Internal Medicine and Pediatrics - F
Flint, Michigan
Revive Research Institute
Lathrup Village, Michigan
Oakland Medical Research Center
Troy, Michigan
Washington University School of Medicine in St. Louis
St Louis, Missouri
Nebraska Medical Research Institute, Inc. - CRN
Bellevue, Nebraska
Machuca Family Medicine
Las Vegas, Nevada
Renown Regional Medical Center Hospital
Reno, Nevada
Hassman Research Institute - HRI - Berlin - CenExel - PPDS
Marlton, New Jersey
AES - DRS - Synexus Clinical Research US, Inc. - New York
New York, New York
Research Carolina Elite
Denver, North Carolina
Pulmonix LLC
Greensboro, North Carolina
Advanced Respiratory and Sleep Medicine, PLLC
Huntersville, North Carolina
Southeastern Research Center
Winston-Salem, North Carolina
OK Clinical Research
Edmond, Oklahoma
The Oregon Clinic
Portland, Oregon
Clinical Research Associates Of Central Pa , Llc
Altoona, Pennsylvania
Allergy & Clinical Immun Assoc
Pittsburgh, Pennsylvania
Medtrial, LLC
Columbia, South Carolina
Showing 40 of 348 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.